The skin is unique in many ways, but no other organ is so visible and demands so much attention and care in both diseased and healthy states.
Our mission is to develop a new generation of premium topical therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. Our unique “hyliQTM” technology is driving a growing product pipeline in key dermatological indications. The technology offers superior bioavailability and stability for many active ingredients combined with a cosmetic acceptability that was previously hard to achieve for topically applied drugs..
Skin disorders and diseases are the fourth leading cause of nonfatal disease burden worldwide, underscoring the importance of dermatology in the field of global health. Skin conditions have significant impact on patients’ well-being, mental health, ability to function, and social participation.
Dermatological treatments are largely divided into external application of drugs (topical therapies), systemic therapies (oral administration or injections of drugs or biologics), physical therapies (for example, light and climate therapies), and laser or surgical therapies. Among these treatments, topical and localized delivery of active ingredients to the diseased skin is the preferred route of treatment in a majority of patients, reducing the risk of systemic side effects.
hyliQTM, the unique and proprietary technology owned by Dermaliq, is designed to provide cutaneous drug delivery with unmatched bioavailability for a wide range of pharmaceutical actives.
The technology enables the development of superior liquid drug products which are characterized by exceptional cosmetic properties.
hyliQTM products are water-free, and do not require preservatives or additional penetration enhancers.
Proprietary hyliQTM carrier molecules transport solubilized active ingredients through the stratum corneum, preferably into the epidermis, into glands, or into hair follicles. By selection of specific carrier molecules, we can customize the properties of our drug products, enhancing targeted penetration into the skin tissues and reducing unwanted side effects.
Preclinical | Phase 1 | Phase 2a | Phase 2b | Phase 3 | |
---|---|---|---|---|---|
|
|||||
|
Preclinical | Phase 1 | Phase 2a | Phase 2b | Phase 3 | |
---|---|---|---|---|---|
|
|||||
|
Preclinical | Phase 1 | Phase 2a | Phase 2b | Phase 3 | |
---|---|---|---|---|---|
|
|||||
|